Guselkumab for treating moderately to severely active ulcerative colitis

  • Technology appraisal guidance
  • TA1094
  • Published: 

History

Documents created during the development process.

Final draft guidance

Invitation to participate

Notes

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6237